Date: 2019-03-12
Type of information: Nomination
Compound: senior vice president cell therapy
Company: Sangamo Therapeutics (USA - CA)
Therapeutic area:
Type agreement: nomination
Action mechanism:
Disease:
Details:
- • On March 12, 2019, Sangamo Therapeutics announced the appointment of Jason Fontenot, as Senior Vice President, Cell Therapy. Dr. Fontenot will oversee Sangamo's growing engineered cell therapy portfolio, including a proprietary immunology pipeline based on chimeric antigen receptor regulatory T cells (CAR-Tregs), a partnership with Sanofi focused on ex vivo genome-editing programs in hemoglobinopathies, and a partnership with Kite, a Gilead Company, to develop allogeneic CAR-T cell therapies in oncology. This new appointment follows the recent appointment of Adrian Woolfson, as Executive Vice President, Research and Development.
- Dr. Fontenot has expertise in lymphocyte biology, cell engineering and immune-mediated disease. The seminal work on regulatory T cells and FOXP3 conducted by Dr. Fontenot and his colleagues transformed the study of immune regulation and produced some of the most highly cited immunology publications of the last 20 years.
- In addition to his scientific expertise, Dr. Fontenot has an extensive background in drug development. Before joining Sangamo, he served as Chief Scientific Officer at Immusoft, leading the development of the company's engineered B cell therapy platform. Prior to Immusoft, Dr. Fontenot served as Head of Exploratory Research at Juno Therapeutics, where he was responsible for advancing the early stage engineered T cell therapy pipeline and overseeing the development of next generation cellular engineering strategies. Before joining Juno, Dr. Fontenot worked for nearly a decade as a group leader in the immunology department at Biogen, where his team focused on T cell biology and immune regulation.
- Dr. Fontenot received his B.S. degree from Louisiana State University and his Ph.D. in Immunology from the University of Washington in Seattle.
Financial terms:
Latest news:
Is general: Yes
